Inflammatory Bowel Disease
Pipeline by Development Stage
Drug Modality Breakdown
Immunology is a $15.0B market in mature growth, driven by blockbuster JAK inhibitors and biologics across multiple therapeutic domains.
Key Trends
- JAK inhibitors and corticosteroid combinations dominate spending (39% combined)
- Multiple patent cliffs emerging 2026-2028, creating generic competition risk
- Robust pipeline with 4,996 trials signals continued innovation and market expansion
Career Verdict
Strong career opportunity for those targeting Medical Affairs, Commercial, or R&D roles, with solid hiring momentum and premium salaries in specialized functions.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | MOUNJARO (TIRZEPATIDE) | Eli Lilly and Company | $2.4B | 16% | PEAK | Growing | 15.7yr |
| 2 | SYMBICORT (BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE) | AstraZeneca | $2.0B | 13% | LOE_APPROACHING | Stable | |
| 3 | JAKAFI (RUXOLITINIB) | Incyte | $1.9B | 13% | LOE_APPROACHING | Declining | 2.6yr |
| 4 | RESTASIS (CYCLOSPORINE) | AbbVie | $1.5B | 10% | PEAK | Stable | 8.0yr |
| 5 | RINVOQ (UPADACITINIB) | AbbVie | $976M | 7% | PEAK | Growing | 11.8yr |
Drug Class Breakdown
dominant class with patent cliff risk
established, mature market segment
driven by single blockbuster
established immunosuppression class
legacy biologic class with competition
Career Outlook
GrowingImmunology offers a maturing but actively growing market with strong corporate investment, deep pipelines, and premium compensation across commercial and clinical functions. The therapeutic area is characterized by complex mechanism-of-action portfolios, frequent label expansion opportunities, and multi-indication blockbusters that require sophisticated Medical Affairs and Commercial expertise. Patent cliff risk on JAK inhibitors creates both disruption and opportunity for those skilled in competitive positioning and pipeline strategy.
Breaking In
Enter through Medical Affairs, Clinical Operations, or Commercial Training programs at large companies (J&J, AbbVie, Bristol Myers Squibb); a foundation in immunology mechanisms is valuable but trainable.
For Experienced Professionals
Leverage patent cliff risk to position yourself in competitive differentiation, pipeline strategy, or M&A integration roles, where demand for immunology expertise is highest.
In-Demand Skills
Best For
Hiring Landscape
Immunology hiring totals 340 open positions with strong demand across Medical Affairs (110 roles, $257K avg), Commercial (83 roles, $270K avg), and R&D (31 roles, $387K avg). Johnson & Johnson, Bristol Myers Squibb, and AbbVie are the top recruiters, reflecting their portfolio depth and market dominance. Compensation is competitive, particularly in R&D and Clinical Operations.
Top Hiring Companies
By Department
Strong hiring demand with premium compensation in Medical Affairs and Commercial roles; R&D positions command highest salaries but are less abundant.
Competitive Landscape
22 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 26 trials with date data
Clinical Trials (26)
Total enrollment: 17,347 patients across 26 trials
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
ENhanced Recovery in CHildren Undergoing Surgery
Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease
Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
LMT503 First-in-human SAD, MAD, and FE Study
Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants
Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease
Characterizing Inflammatory Bowel Disease With 68Ga-FAPI PET/CT
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
Bone Marrow Stromal Cells for Inflammatory Bowel Diseases
Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Characterization of Phenotype and Genotype of Early Onset Enteropathies
The Altitude Inflammatory Bowel Disease Study
OPERA Database - Crohn's Protocol
Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy
Managing Inflammatory Bowel Disease
Genetic Studies of Inflammatory Bowel Disease
Gene Expression in Inflammatory Bowel Disease
Immune Regulation in Ulcerative Colitis or Crohn s Disease
Related Jobs in Immunology
OT Automation Lead
Head of Centre of Expertise Aseptic Processes & Global Technical Operations- Manufacturing Technology & Science
GXP System and Process Manager
Técnico/a Químico/a para Producción
Ingeniero/a para Sistemas de Control y Automatización
Gastroenterology Health & Science Sales Specialist - Allentown, PA
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.